The New England journal of medicine
-
Comment Letter
Antiretroviral preexposure prophylaxis for HIV prevention.
-
Randomized Controlled Trial Multicenter Study Comparative Study
Cardiovascular events and intensity of treatment in polycythemia vera.
Current treatment recommendations for patients with polycythemia vera call for maintaining a hematocrit of less than 45%, but this therapeutic strategy has not been tested in a randomized clinical trial. ⋯ In patients with polycythemia vera, those with a hematocrit target of less than 45% had a significantly lower rate of cardiovascular death and major thrombosis than did those with a hematocrit target of 45 to 50%. (Funded by the Italian Medicines Agency and others; ClinicalTrials.gov number, NCT01645124, and EudraCT number, 2007-006694-91.).